Noonan Syndrome

  1. Overview and Epidemiology
  2. Genetics and RAS-MAPK Pathway
  3. Facial Features and Dysmorphology
  4. Cardiovascular Manifestations
  5. Growth and Endocrine Issues
  6. Hematology and Cancer Risk
  7. Cognitive and Neurodevelopmental Features
  8. Other Clinical Manifestations
  9. Diagnosis
  10. Management and Treatment
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Overview and Epidemiology

Noonan syndrome is an autosomal dominant genetic disorder caused by gain-of-function mutations in genes encoding components of the RAS-MAPK signaling pathway. It is one of the most common genetic syndromes associated with congenital heart disease, occurring in approximately 1 in 1,000 to 1 in 2,500 live births, making it as prevalent as Down syndrome in some estimates. Noonan syndrome affects males and females equally and occurs across all ethnic groups.

The condition was formally delineated in 1963 by pediatric cardiologist Jacqueline Noonan, who described a group of patients with short stature, webbed neck, pectus deformity, and pulmonary valve stenosis — features that resembled Turner syndrome but occurred in males as well as females, and with a normal chromosomal karyotype. The syndrome is sometimes informally called "Turner syndrome with a normal karyotype," though the two conditions have distinct genetic causes and some differing features.

Because Noonan syndrome is classified as a RASopathy — a family of syndromes sharing dysregulated RAS-MAPK pathway signaling — it overlaps phenotypically with related conditions including Costello syndrome, cardio-facio-cutaneous (CFC) syndrome, Leopard syndrome (NSML), and Neurofibromatosis type 1 (NF1). These disorders share dysmorphic features, cardiac defects, short stature, variable intellectual disability, and elevated cancer risk, driven by different mutations affecting nodes in the same signaling cascade.

Approximately 60% of cases are sporadic (de novo mutations), while the remainder are inherited from an affected parent. Variable expressivity is characteristic: within the same family, affected individuals may range from severely affected to clinically very mild.

Back to Table of Contents

Genetics and RAS-MAPK Pathway

Noonan syndrome arises from heterozygous gain-of-function (or loss-of-inhibition) mutations in genes encoding proteins that relay signals through the RAS-RAF-MEK-ERK cascade — a fundamental intracellular signaling pathway governing cell proliferation, differentiation, survival, and migration. Dysregulation of this pathway during embryonic development produces the multisystem abnormalities characteristic of Noonan syndrome.

The major causative genes and their approximate frequencies in Noonan syndrome are:

The inheritance pattern is autosomal dominant, meaning a single mutant allele is sufficient to cause disease. Affected parents have a 50% probability of transmitting the mutation to each child. However, because of variable expressivity, an affected parent may be very mildly affected while their child has more prominent features. Recurrence risk counseling must account for germline mosaicism when neither parent appears affected on testing.

The RAS-MAPK pathway mutations in Noonan syndrome provide the mechanistic link to the elevated cancer risk seen in this syndrome — particularly PTPN11 mutations and JMML, since the same pathway mutations found in the germline can arise somatically in leukemic clones.

Back to Table of Contents

Facial Features and Dysmorphology

Noonan syndrome produces a distinctive but highly variable facial gestalt that changes significantly with age, making diagnosis more straightforward in infants and young children than in adults, where features become subtler. Artificial intelligence facial recognition tools (notably the FaceAge/Face2Gene system) have been evaluated in research settings and may assist clinicians facing uncertain diagnoses.

Key craniofacial features include:

Skin and hair findings are especially prominent in SOS1-associated Noonan syndrome and can include curly or woolly hair, keratosis pilaris (rough skin patches on the upper arms), and scattered lentigines (dark freckles). When lentigines are very numerous and accompanied by EKG conduction abnormalities and Noonan features, the condition is classified as LEOPARD syndrome (Lentigines, ECG abnormalities, Ocular hypertelorism, Pulmonary valve stenosis, Abnormal genitalia, Retardation of growth, Deafness) — now termed NSML (Noonan Syndrome with Multiple Lentigines), caused by loss-of-function PTPN11 mutations.

The facial features evolve substantially with age: the coarse neonatal gestalt softens by adolescence, and adults may appear only mildly affected. Triangular face shape, deep nasolabial folds, and a prominent high-bridged or pinched nose are relatively consistent in older individuals.

Back to Table of Contents

Cardiovascular Manifestations

Congenital heart disease (CHD) is present in approximately 80–90% of individuals with Noonan syndrome, making it the most medically significant system involvement and the feature most responsible for early morbidity and mortality. The cardiac phenotype in Noonan syndrome is distinctive and differs in important ways from cardiac defects seen in the general CHD population.

Pulmonary valve stenosis (PVS) is the most common defect, occurring in approximately 50–60% of Noonan syndrome cases. A critical distinguishing feature is that the pulmonary valve in Noonan syndrome is characteristically dysplastic — the leaflets are thickened, redundant, and myxomatous rather than thin and domed. This distinction matters clinically because dysplastic valves respond less well to balloon pulmonary valvuloplasty than the typical rheumatic or calcific stenotic valve, and surgical valvotomy or valve replacement is more frequently required.

Hypertrophic cardiomyopathy (HCM) occurs in approximately 20–30% of Noonan syndrome patients, in contrast to its much lower prevalence in the general population. HCM in Noonan syndrome is particularly associated with RAF1 and RIT1 mutations and can be severe in infancy, when it overlaps with the condition previously termed LEOPARD syndrome–HCM. Unlike sarcomeric HCM (the most common form in the general population, caused by MYH7/MYBPC3 mutations), Noonan-associated HCM is non-sarcomeric and arises from dysregulated MEK-ERK signaling in cardiomyocytes. Prognosis is worse when HCM presents in infancy, and the cardiomyopathy can progress to heart failure. Some patients require cardiac transplantation.

Other cardiac defects seen in Noonan syndrome include:

Arrhythmias — particularly supraventricular tachycardia — are more frequent in Noonan syndrome than in the general population, and the ECG may show a characteristic superior or leftward QRS axis, which is a useful diagnostic clue. Echocardiography is recommended for all individuals with suspected Noonan syndrome at the time of diagnosis, with ongoing cardiology follow-up individualized to the specific defect.

Back to Table of Contents

Growth and Endocrine Issues

Short stature is one of the most consistent features of Noonan syndrome, affecting the large majority of patients. Mean adult heights in untreated Noonan syndrome are approximately 162–168 cm in males and 152–155 cm in females, representing a mean deficit of roughly 2 standard deviations below population norms. Growth velocity is typically normal in the first year but then declines, with a characteristically absent or blunted pubertal growth spurt and delayed bone age.

The mechanism of short stature in Noonan syndrome is multifactorial. Growth hormone (GH) deficiency or GH insensitivity is present in approximately 50% of patients — RAS-MAPK pathway dysregulation impairs GH signaling downstream of the GH receptor (through JAK2-STAT5), reducing the growth response to GH even when GH secretion itself is adequate.

Recombinant human growth hormone (rhGH) therapy is approved by the FDA for Noonan syndrome and has demonstrated significant benefit in multiple clinical trials. Treatment typically achieves a height gain of 1–2 standard deviations over 4–6 years. Initiation in early childhood, before the pubertal window closes, yields the best outcomes. Important considerations include:

Puberty is frequently delayed in both sexes, though fertility is not consistently impaired in females. The pubertal delay means that linear growth continues longer than average, partially compensating for the growth deficit. Cryptorchidism (undescended testes) affects approximately 80% of males with Noonan syndrome at birth, making it one of the most common reasons for referral in infant males. If untreated, cryptorchidism is associated with reduced fertility and increased testicular malignancy risk; orchiopexy is recommended in the first 1–2 years of life. Despite high rates of cryptorchidism, many males with Noonan syndrome are fertile.

Feeding difficulties in infancy are extremely common and can be severe, sometimes requiring nasogastric or gastrostomy feeding. Contributing factors include hypotonia, structural upper airway abnormalities, oromotor dysfunction, and cardiac disease. Feeding usually improves by 18 months to 2 years of age, though nutritional support during infancy is often necessary.

Back to Table of Contents

Hematology and Cancer Risk

Individuals with Noonan syndrome have a well-documented increased risk of certain hematologic malignancies, arising directly from the dysregulated RAS-MAPK signaling that characterizes this condition. Somatic mutations in the same pathway genes (particularly PTPN11 and KRAS) are among the most common driver mutations in human cancers, explaining why germline activation of these genes carries elevated malignancy risk.

Juvenile myelomonocytic leukemia (JMML) is the most strongly associated malignancy. JMML is a rare but aggressive childhood myeloproliferative disorder characterized by overproduction of monocytes and infiltration of liver, spleen, and bone marrow. It occurs in approximately 1% of Noonan syndrome patients overall, but the risk is heavily concentrated in those with PTPN11 mutations — up to 200-fold higher risk than the general childhood population. JMML in Noonan syndrome may follow a milder and sometimes spontaneously remitting course compared to sporadic JMML, but distinction from the more aggressive sporadic form requires expert hematologic assessment and molecular analysis. Hematopoietic stem cell transplantation (HSCT) remains the only curative option for progressive disease.

Bleeding tendency is present in a substantial minority of Noonan syndrome patients and contributes to surgical risk. The coagulopathy is heterogeneous and may involve:

Pre-operative coagulation studies are strongly recommended before any surgical procedure in Noonan syndrome. A detailed bleeding history (easy bruising, prolonged bleeding after dental extraction or prior surgery, family bleeding history) should be obtained at initial evaluation. Hematology consultation is appropriate for identified coagulopathies.

Other malignancies reported at elevated frequency include certain solid tumors (neuroblastoma, rhabdomyosarcoma, low-grade glioma), though absolute risks remain low. Routine cancer surveillance protocols beyond standard pediatric care are not currently recommended outside of JMML vigilance in PTPN11-positive patients.

Back to Table of Contents

Cognitive and Neurodevelopmental Features

Cognitive and neurodevelopmental involvement in Noonan syndrome is variable and, on average, milder than in Down syndrome. Approximately 25% of individuals with Noonan syndrome have mild intellectual disability (IQ 50–70), while the majority have borderline or low-average intelligence. A substantial proportion have normal intelligence; some are high achieving academically. The specific causative gene strongly influences cognitive outcome: SOS1 mutations are associated with near-normal intellect, while KRAS and certain BRAF mutations tend toward more severe intellectual disability.

Learning disabilities — even in the absence of frank intellectual disability — are common. Difficulties with reading, spelling, and mathematics are frequently reported. Visuospatial processing weaknesses and problems with attention and working memory are characteristic. Specific language impairment (SLI) and delayed speech onset affect a significant subset, related in part to recurrent otitis media and conductive hearing loss (present in 15–40% of patients).

Attention-deficit/hyperactivity disorder (ADHD) is disproportionately prevalent in Noonan syndrome, estimated at 30–50% of affected children, compared to approximately 7% in the general pediatric population. Standard ADHD treatments (stimulant medications, behavioral therapies) are generally effective, though monitoring for cardiac effects of stimulants is appropriate given the high prevalence of CHD.

Psychosocial adjustment is a key concern. Short stature, delayed puberty, dysmorphic features, and school learning difficulties can collectively affect self-esteem and peer relationships. Psychological support and targeted educational interventions (individualized education plans, speech-language therapy) meaningfully improve outcomes. Most adults with Noonan syndrome lead independent lives, are employed, and report good quality of life, particularly when cardiac disease is well-managed.

Back to Table of Contents

Other Clinical Manifestations

Noonan syndrome affects multiple organ systems beyond the cardiac, growth, and cognitive domains, requiring comprehensive multidisciplinary surveillance.

Musculoskeletal:

Lymphatic:

Ophthalmologic:

Renal: Structural renal anomalies (duplicated collecting system, hydronephrosis, renal dysplasia) occur in approximately 10% of patients and may be identified on prenatal ultrasound.

Skin: Keratosis pilaris ulerythema ophryogenes (KPUO) — erythematous follicular papules affecting the cheeks and lateral eyebrows — is a relatively specific finding for RASopathies, particularly in SOS1-associated Noonan syndrome.

Prenatal presentation: Noonan syndrome is increasingly identified prenatally. Suggestive features on second-trimester ultrasound include increased nuchal translucency (like Down syndrome), pleural effusions, polyhydramnios, pulmonary valve stenosis, and renal anomalies — with a normal 46,XX or 46,XY karyotype (ruling out Turner syndrome and Down syndrome respectively). Prenatal diagnosis is confirmed by molecular testing of chorionic villus sampling or amniotic fluid.

Back to Table of Contents

Diagnosis

The diagnosis of Noonan syndrome rests primarily on clinical recognition of the characteristic facial gestalt, cardiac defects, and associated features, confirmed by molecular genetic testing. There is no single pathognomonic finding — the diagnosis is a pattern recognition exercise, and severity varies so widely that mildly affected individuals may escape diagnosis until an affected child is identified.

Clinical scoring systems such as the van der Burgt score (1994) were developed to standardize diagnosis before gene testing was available, assigning points to facial features, cardiac defects, short stature, pectus, family history, and other features. A score ≥5 is considered confirmatory for clinical diagnosis. While superseded in many centers by genetic testing, scoring systems remain useful for guiding test prioritization.

Molecular genetic testing is the current standard for confirmation and genotype-phenotype correlation:

Importantly, a negative genetic test does not exclude Noonan syndrome in a clinically convincing case, as some causative genes remain to be identified. Clinical diagnosis should drive management decisions when molecular testing is uninformative.

Differential diagnosis includes:

Back to Table of Contents

Management and Treatment

Management of Noonan syndrome is multidisciplinary and lifelong, guided by the specific cardiac defect, gene mutation, and severity of involvement. No targeted molecular therapy is currently approved, though RAS-MAPK pathway inhibitors (MEK inhibitors, used in cancer) are under investigation in preclinical and early clinical models.

Cardiology:

Growth:

Hematology:

Neurodevelopment and education:

Surgical considerations:

Genetic counseling: For families with an affected member, cascade testing of first-degree relatives and recurrence risk counseling (50% per child) are recommended. Prenatal diagnosis by molecular testing of CVS or amniocentesis is available for known familial mutations.

Back to Table of Contents

Key Research Papers

  1. Tartaglia M et al. (2001) — Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet.
    PMID: 11704759
  2. Roberts AE et al. (2007) — Noonan syndrome is caused by gain-of-function mutations in SOS1 encoding a Ras/Rho guanine nucleotide exchange factor. Nat Genet.
    PMID: 17143282
  3. Pandit B et al. (2007) — Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet.
    PMID: 17435756
  4. van der Burgt I (2007) — Noonan syndrome. Orphanet J Rare Dis.
    PMID: 17284299
  5. Tartaglia M, Gelb BD (2010) — Disorders of dysregulated signal traffic through the RAS-mitogen-activated protein kinase pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci.
    PMID: 20887202
  6. Sharland M et al. (1992) — A clinical study of Noonan syndrome. Arch Dis Child.
    PMID: 1416040
  7. Burch M et al. (1993) — Cardiomyopathy in Noonan syndrome. Br Heart J.
    PMID: 7682028
  8. Romano AA et al. (2010) — Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics.
    PMID: 20937660
  9. Limal JM et al. (2006) — Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab.
    PMID: 16537682
  10. Jongmans M et al. (2011) — Risk of malignancy in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet.
    PMID: 21224891
  11. Smpokou P et al. (2012) — Malignancy in Noonan syndrome and related disorders. Clin Genet.
    PMID: 21651527
  12. Sanchez-Andres A (2016) — Bleeding manifestations in Noonan syndrome. Haemophilia.
    PMID: 11929594

Back to Table of Contents

Connections

Back to Table of Contents